SG Americas Securities LLC Purchases 2,763 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX)

SG Americas Securities LLC lifted its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Rating) by 25.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,633 shares of the company’s stock after acquiring an additional 2,763 shares during the period. SG Americas Securities LLC’s holdings in Edgewise Therapeutics were worth $122,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. EcoR1 Capital LLC lifted its stake in Edgewise Therapeutics by 48.0% in the 3rd quarter. EcoR1 Capital LLC now owns 3,493,194 shares of the company’s stock valued at $34,373,000 after purchasing an additional 1,133,386 shares during the last quarter. FMR LLC lifted its stake in Edgewise Therapeutics by 11.7% in the 2nd quarter. FMR LLC now owns 2,815,284 shares of the company’s stock valued at $22,410,000 after purchasing an additional 293,834 shares during the last quarter. Citadel Advisors LLC lifted its stake in Edgewise Therapeutics by 8.8% in the 3rd quarter. Citadel Advisors LLC now owns 2,761,724 shares of the company’s stock valued at $27,175,000 after purchasing an additional 223,706 shares during the last quarter. BlackRock Inc. lifted its stake in Edgewise Therapeutics by 3.0% in the 3rd quarter. BlackRock Inc. now owns 2,115,470 shares of the company’s stock valued at $20,817,000 after purchasing an additional 61,902 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Edgewise Therapeutics by 42.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,751,845 shares of the company’s stock valued at $17,239,000 after purchasing an additional 525,277 shares during the last quarter.

Insider Activity at Edgewise Therapeutics

In other Edgewise Therapeutics news, CEO Kevin Koch sold 3,203 shares of Edgewise Therapeutics stock in a transaction dated Tuesday, May 2nd. The shares were sold at an average price of $8.90, for a total value of $28,506.70. Following the sale, the chief executive officer now owns 7,213 shares of the company’s stock, valued at $64,195.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Kevin Koch sold 3,203 shares of Edgewise Therapeutics stock in a transaction dated Tuesday, May 2nd. The shares were sold at an average price of $8.90, for a total value of $28,506.70. Following the completion of the transaction, the chief executive officer now owns 7,213 shares in the company, valued at $64,195.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Joanne M. Donovan sold 3,254 shares of Edgewise Therapeutics stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $8.90, for a total transaction of $28,960.60. Following the completion of the transaction, the chief marketing officer now owns 9,960 shares of the company’s stock, valued at approximately $88,644. The disclosure for this sale can be found here. Insiders have sold 11,437 shares of company stock valued at $101,789 over the last ninety days. Corporate insiders own 37.05% of the company’s stock.

Analyst Ratings Changes

Separately, Truist Financial started coverage on shares of Edgewise Therapeutics in a research report on Monday, May 1st. They set a “buy” rating for the company.

Edgewise Therapeutics Price Performance

EWTX opened at $9.02 on Tuesday. The company’s 50-day moving average is $7.59 and its 200 day moving average is $8.89. Edgewise Therapeutics, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $14.33. The firm has a market capitalization of $570.76 million, a P/E ratio of -7.10 and a beta of -0.13.

Edgewise Therapeutics (NASDAQ:EWTX – Get Rating) last released its quarterly earnings results on Thursday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. On average, equities research analysts expect that Edgewise Therapeutics, Inc. will post -1.66 earnings per share for the current year.

About Edgewise Therapeutics

(Get Rating)

Edgewise Therapeutics, Inc, a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial.